Hepatitis C virus and liver transplantation

Clinics in Liver Disease

Volumn 5, Issue 4, 2001, Pages 1073-1090

  Ahmed, Aijaz ^a,b   Keeffe, Emmet B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HLA ANTIGEN; INTERFERON; RECOMBINANT INTERFERON; RIBAVIRIN;

ALLOGRAFT; CELLULAR IMMUNITY; DISEASE SEVERITY; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE DEFICIENCY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; RECURRENT INFECTION; REVIEW; SURVIVAL; VIREMIA;

EID: 0034772546     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70210-5     Document Type: Article

References (99)

1. Hepatitis C virus infection in the United States
2. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States
3. Immunohistochemical evidence of immunophatogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation
4. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation
5. Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation
6. Fibrosis progression in recurrent hepatitis C virus (HCV) disease: Differences between the U.S. and Europe
7. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection
8. HCV-related fibrosis progression following liver transplantation: Increase in recent years
9. Hepatitis C virus and the host: An imbalance induced by immunosuppression?
10. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
11. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
12. Impact of hepatitis G virus co-infection on the course of hepatitis C virus infection before and after liver transplantation
13. Anti-hepatitis C virus core IgM antibodies correlate with hepatitis C recurrence and its severity in liver transplant patients
14. Long-term outcome of hepatitis C virus infection after liver transplantation
15. Health-related quality of life after transplantation: A meta-analysis
16. Interactions between alcohol and hepatitis viruses in the liver
17. Posttransplantation prevention and treatment of recurrent hepatitis C
18. Viral hepatitis and liver transplantation
19. Recurrent hepatitis C after liver transplantation
20. Outcome of liver retransplantation (ReOLTx) for recurrent hepatitis C infection
21. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus
22. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation
23. Predictors of patient and graft survival following liver transplantation for hepatitis C
24. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database
25. Quantitation of hepatitis C virus RNA in liver transplant recipients
26. Liver transplantation for chronic viral disease
27. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients
28. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation
29. Quality of life of hepatitis B and C patients after liver transplantation
30. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation
31. Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apoptosis after liver transplantation for hepatitis C
32. Liver transplantation for chronic viral hepatitis
33. Living donor liver transplantation in Kyushu University
34. Spontaneous clearance of hepatitis C virus infection post-liver transplantation is associated with rapidly changing quasispecies: A single case report
35. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus
36. Virology of hepatitis C virus
37. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
38. Poor prognosis of patients retransplanted for recurrent liver disease due to hepatitis C virus
39. Influence of genotypes of hepatitis C on the severity of recurrent liver disease after liver transplantation
40. An open trial of interferon alfa recombinant for C after liver transplantation hepatitis: Antiviral effects and risk of rejection
41. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
42. Hepatitis C viral infection in liver transplant recipients
43. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: A comparative study
44. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions
45. Long-term outcome of hepatitis C infection after liver transplantation
46. Hepatitis C virus genotypes in liver transplant recipients: Impact on posttransplant recurrence, infections, and response to interferon-alpha and outcome
47. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience
48. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression
49. Clinical outcome of hepatitis C as a function of mode of transmission
50. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features
51. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: A molecular and histologic study
52. Hepatitis B and C coinfections and persistent hepatitis B infections: Clinical outcome and liver pathology after transplantation
53. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
54. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft
55. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
56. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors
57. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Association for the Study of Liver Diseases
58. The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation
59. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases
60. Genetic heterogeneity of hepatitis C virus. The clinical significance of genotypes and quasispecies behavior
61. Effect of interferon and ribavirin prophylaxis after liver transplantation in HCV-RNA positive patients
62. Long term outcome of liver transplantation for viral hepatitis: Is there a need to re-evaluate patient selection?
63. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: Relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection
64. Serum hepatitis C virus RNA levels and histologic findings in liver allografts with early recurrent hepatitis C
65. Quality of life in long-term survivors after liver transplantation: Impact of recurrent viral hepatitis C virus hepatitis
66. Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation
67. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate
68. A controlled study of hepatitis C transmission by organ transplantation
69. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation
70. Natural history of liver fibrosis progression in patients with chronic hepatitis C
71. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following liver transplantation: Relationship with rejection episodes
72. Graft loss following liver transplantation in patients with chronic hepatitis C
73. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation
74. Cytomegalovirus viremia. Risk factor for allograft cirrhosis after liver transplantation for hepatitis C
75. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury
76. Hepatitis C infection in patients undergoing liver retransplantation
77. Liver transplantation
78. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation
79. Humoral immune response to hepatitis C after liver transplantation: Assessment of a new recombinant immunoblot assay
80. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
81. Liver transplantation in the United States from 1987-1998: Updated results from the Pitt-UNOS liver transplant registry
82. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
83. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation
84. Retransplantation for recurrent hepatitis C
85. Variability of hepatitis C virus
86. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C
87. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation
88. Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: Effect of viral hepatitis D
89. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation
90. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors
91. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
92. Clinical outcomes after transfusion-associated hepatitis C
93. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts
94. Epidemiology of hepatitis C: Geographic differences and temporal trends
95. Epidemiology and natural history of hepatitis C infections in liver transplant recipients
96. Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients
97. Interferon-α therapy for hepatitis C virus infection after liver transplantation
98. The long-term pathological evolution of chronic hepatitis C
99. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia